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Abstract: Introduction: Iron-chelating therapy with deferoxamine in
patients with thalassemia major has dramatically improved the
prognosis of this disease. However, the limitations of this treatment have
stimulated the design of alternative orally active iron chelators.
Objective: To compare the effectiveness and safety of, and compliance
with, oral deferiprone (L1), and deferoxamine, in thalassemia major
patients. Methods: All patients were followed up in one center in
Lebanon. Sixteen patients were on L1 (75 mg/kg/d), and 40 patients on
subcutaneous deferoxamine (20–50 mg/kg/d). Serum ferritin level,
urinary iron excretion (UIE) and side effects were monitored over a two
year period. Results: Patients on L1 had an initial serum ferritin
concentration of 3663t566 mg/l (meantSEM), that dropped to
2599t314 at 6 months (p<0.02; paired t-test), and stabilised at that level
over the 24 months follow up. Patients on deferoxamine had an initial
mean serum ferritin concentration of 3480t417 (NS compared to the L1
group), which dropped gradually to 3143t417 (p<0.05) and 2819t292
(p<0.02) at 6 and 24 months, respectively. The most common adverse
reactions associated with L1 were arthralgia and nausea, but they did not
necessitate stopping the drug. Conclusion: L1 had comparable efficacy as
deferoxamine with minimal side effects and better compliance. Provided
long term side effects are not encountered, L1 seems to be a valuable
alternative iron chelator for patients unable or unwilling to use
deferoxamine effectively.
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In patients with b-thalassemia major, an adequate
transfusion program prevents the complications of
anemia and compensatory bone marrow expansion,
permits normal development throughout child-
hood, and extends survival (1). However, due to
lack of an effective means for excreting excess iron,
blood transfusion results in an inexorable accumu-
lation of tissue iron that may cause hepatic and
endocrine abnormalities, growth retardation, dia-
betes mellitus and cardiac failure (2, 3). Clinical
trials with deferoxamine (Desferal1) have proved
the effectiveness of iron chelation as a therapeutic
approach to iron overload, with a decrease in the
body iron burden, prevention of organ dysfunction,
and consequently an improved survival (4, 5).
Deferoxamine is currently the only iron-chelating
agent approved internationally for clinical use (1, 3,
4). In a dose of 25–50 mg/kg/d, it results in a
negative iron balance in most patients with a body
iron burden about 5–10 times the normal level (2, 6,
7).
However, treatment with deferoxamine is cum-
bersome, expensive, unpleasant and presents some
long term toxic effects (8). First, many patients find
difficulty in complying with daily subcutaneous
deferoxamine administration which is burdensome,
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painful, and time consuming. Second, infusions are
not given continuously, allowing toxic non-trans-
ferrin bound iron (NTBI) to accumulate in plasma
between infusions (2, 6). Third, over 90% of the
world’s patients with thalassemia can not afford
deferoxamine ($5000 to $15,000 a year) (9). Fourth,
adverse effects are associated with deferoxamine
including allergy, pain at the site of infusion, ocular
and auditory abnormalities, neurotoxicity, changes
in renal function, and failure of linear growth in
young children (1).
Thus, in spite of the proven efficacy of deferox-
amine, there was a great need for the development
of an alternative iron chelator based on three main
criteria, namely oral activity, low cost, and low
toxicity (5, 10). Of all the new iron-chelating drugs
available today, only deferiprone (1, 2-dimethyl-3-
hydroxypyridin-4-one; L1) has been introduced for
clinical use as an orally effective substitute for
deferoxamine (1, 5, 11). The efficacy of L1 in
reducing body iron burden in patients with iron
overload has been uncertain, despite an increase in
urinary iron excretion (1, 12). Adverse reactions
associated with the use of deferiprone include
agranulocytosis, arthropathy, zinc deficiency, and
gastrointestinal side effects (13). We hereby report
the results of an open trial comparing subcuta-
neously administered deferoxamine with orally
administered L1.
Patients and method
We studied 57 patients with transfusion-dependent
thalassemia major, ranging in age between 12 and
28 yr, who were evaluated periodically in the
Chronic Care Center, a Lebanese charitable institu-
tion. Each patient received regular transfusions of
packed red cells at 3- to 4-week intervals to
maintain their hemoglobin concentration at a
level above 9 g/dl. All patients were on deferox-
amine for a period ranging from 4 to 24 yr.
Seventeen patients (15 had thalassemia major, 1
thalassemia intermedia and 1 sickle-thalassemia)
received L1 because they were not compliant or
unable to take deferoxamine because of severe
reactions to the drug. Non-compliance was defined
as discontinuation of the drug for at least one
month or intake of less than 70% of the recom-
mended dose which ranged from 25 to 50 mg/kg/d
according to ferritin level and taken 5 times/week.
These patients, aged 20t1 yr (9 males and 8
females), were given deferiprone (Lipomed, Basel,
Switzerland) orally at a total daily dose of 75 mg/kg
body weight. L1 was given in three divided doses
before meals. The effect of L1 on these patients over
a 12 month period was previously reported (14).
One patient was not compliant and was lost for
follow-up, so he was dropped out from the study.
The remaining 40 patients with thalassemia major,
aged 17t4 yr (21 males and 19 females) received
deferoxamine, (Novartis, Basel, Switzerland). The
daily dose of deferoxamine ranged from 25 to
50 mg/kg/d to be taken at least 5 d each week. The
drug was given by subcutaneous infusions overnight
for 8–12 h. The study was approved by the Ethical
Committee of the Chronic Care Center.
We assessed the efficacy of the chelators by
periodic measurements of serum ferritin concentra-
tions over a 24-month follow up period. In addition,
in patients on L1, a 24-h urinary iron excretion was
performed initially one week after starting the drug
and at 6 and 12 months. Statistical analysis was
performed using Student’s t-test.
Safety was determined by regular patient follow
up with detailed clinical examination. In addition,
patients were asked to fill in side effects ques-
tionnaires. Regular laboratory tests were performed
for patients on L1 including full blood count, liver
and renal function, serum immunoglobulins, and
antinuclear and rheumatic factor. Urinary zinc
excretion was measured one week after starting L1
and every 6 months thereafter.
Results
Efficacy of L1
In the 16 patients receiving L1, mean serum ferritin
level showed a decline with time from an initial
meantSEM of 3663t566 mg/l (range 1005–9787)
to 2599t314 (range 575–4206) at 6 months, and
2716t461 (range 944–7117) at 24 months after
starting treatment (p<0.03 and p<0.05, respec-
tively) (Fig. 1).
Urinary iron excretion (UIE) one week after
starting L1 therapy was 20.7t3.2 mg/24 h (range
0.3–42.7) and dropped to 10.5t1.7 (range 0.07–25)
and 13.7t1.8 (range 0.3–28) at 6 and 12 months
after starting L1 (both p<0.01 compared to initial
UIE). There was a positive correlation between
initial serum ferritin level and UIE (r=0.57,
p<0.019), but this correlation did not persist over
the follow up period (r=0.006 and r=0.3 at 6 and
12 months, respectively).
Efficacy of deferoxamine
In the 40 patients receiving deferoxamine, mean
serum ferritin level showed a decrease with time
from an initial meantSEM of 3480t417 mg/l
(range 829–10,540) to 3143t378 (range 591–
11734) (p<0.05) at 6 months, and 2819t292
(453–8602) (p<0.02) at 24 months (Fig. 1).
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Safety of L1
The most common reaction that was associated
with the administration of L1 was an orange
discoloration of the urine. The most common
adverse effect was joint pain (mostly large joints),
stiffness or swelling reported in six patients (37.5%),
two of whom had moderate to severe symptoms
that did not require a decrease or discontinuation of
L1 and the other four had mild symptoms. Nausea,
especially in the first month of treatment, was
reported in seven patients (43.7%). Other side
effects included headache (4 patients), skin rash (2
patients), occasional decrease in appetite (2
patients), fatigue (2 patients), abdominal discom-
fort, mouth ulcers, and sore throat (each in one
patient).
Complete blood counts, obtained periodically in
all patients, did not change significantly during
treatment. Neither reduction of dose nor cessation
of L1 was required because of a change in the blood
count in any patient. Only two patients had a
transient decrease in neutrophil count to 1.38r109
and 1.44r109/l that was not reproduced on weekly
follow up studies. These two patients had a history
of recent viral infection.
There was a non-significant increase in urinary
Zn excretion from 441t37 to 515t73 mg/24 h
(p=0.35).
Because of few report of L1-associated systemic
lupus erythematosus, tests for antinuclear anti-
bodies and rheumatoid factor were performed every
3 months. No significant changes in antinuclear
antibodies or rheumatoid factor were noted; we did
not detect any positive qualitative ANF at any time
during the trial.
Abnormal liver enzymes, defined as an increase in
serum aspartate transaminase (AST) of >2 times
the upper limit of normal, were detected in 13
patients, eight of whom were HCV positive. In this
subgroup, there was no change in the level of AST
during L1 therapy (85t14 and 96t19 IU/l at time
0 and 24 months, respectively). The other five
patients had a transient increase in AST (50t7,
79t10, 51t9 and 47t5 at times 0, 6, 12 and 24
months, respectively). All patients maintained
normal levels of blood urea, serum creatinine, as
well as normal fasting glucose tolerance tests.
Safety of deferoxamine
The most common side effects observed in patients
on deferoxamine were pain, tenderness, itching,
erythema, swelling, induration, lipodystrophy, and
a burning sensation at the site of infusion reported
in 34 patients (85%). In a few cases, increased heart
rate (6 patients), disturbances of vision and hearing
(5 patients), dizziness (4 patients), growth retarda-
tion (3 patients), and leg cramps (one patient) were
also observed.
Compliance
In patients on L1, compliance was apparently
excellent in all patients as assessed by the patient’s
history, parental evidence, and usage of tablets
provided in just-sufficient quantities between check
up visits. On the other hand, in patients on
deferoxamine, compliance was considered to be
rated good in 24 patients (60%), and poor in 16
patients (40%), assessed mainly by counting vials
given to patients and returned after usage.
Discussion
The results here confirm that L1 is effective at
increasing urinary iron excretion in patients with
transfusional iron-overload. However, although
patients received comparable doses of L1, urinary
iron excretion varied considerably from patient to
patient. The wide variation in iron excretion among
the patients may relate partly to a wide range in
body iron stores, with iron excretion being greater
in those with higher serum ferritin level (r=0.56,
p<0.02) assuming that serum ferritin level may
correlate with total iron body burden. Iron excre-
tion also relates to the area under the curve of free
deferiprone in plasma after a single oral dose (15).
The drug is glucuronidated at a different rate in
different patients. Efficacy will be affected, since
glucuronidation inactivates the drug’s iron binding
sites. The lack of efficacy in some patients, despite
high iron body loads, may be the result of
particularly fast glucuronidation of deferiprone
(15).
In general, the mean daily intake of iron from
transfusion is 0.5 mg/kg/d. Five of 16 patients tested
Fig. 1. Effect of deferiprone (L1) and deferoxamine on
serum ferritin level in thalassemia patients during 24 months
follow up. *p<0.03 and **p<0.05 compared with initial
ferritin level (time 0). Values are expressed as mean and
SEM.
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showed UIE greater than this on a daily total dose
of 75 mg/kg/d one week after L1 administration.
After 6 months and one year, this rate of excretion
was sustained in only one patient. The reduction in
UIE with time could be secondary to a reduction in
body iron stores (as assessed indirectly by serum
ferritin level); however, in our study there was no
correlation between UIE and serum ferritin level at
6 and 12 months after starting L1. This finding is
similar to results of other studies where UIE
decreased with time without any correlation with
serum ferritin (16). The other possible cause for the
decrease in UIE over time could be the reduced
absorption associated with long term use of L1 or
increased metabolism with a progressive decrease in
serum L1 trough levels (17). Since excretion
depends mainly on the dose of L1 (11, 18), this
raises the question whether L1 at this dose can
induce a negative iron balance in these patients. In a
previous report (18), a negative iron balance could
be achieved with higher L1 doses; the mean UIE at a
dose of 85–119 mg/kg/d was comparable with that
achieved with deferoxamine at a dose of 40 to
50 mg/kg/d. A fall in serum ferritin was noted in 14/
16 patients (87.5%) after 6 months, and in 12/16
patients (75%) after 12 and 24 months of L1
administration. There was a statistically significant
decrease in mean serum ferritin concentration at 6,
12 and 24 months after starting L1 (Fig. 1).
Changes in serum ferritin was not encountered in
all previous studies, some showing a significant
decrease (18–21); while others showing no change
(22–24). This discrepancy could be explained by the
different duration of treatment, severity of iron
overload before starting L1, dosage, compliance
and possibly drug source. In our study, serum
ferritin concentration dropped abruptly at 6 months
and then seemed to plateau. Although a previous
study showed a decline of serum ferritin over time
(19), Olivieri et al. (25) found a plateau or even an
upward trend of serum ferritin similar to our
findings, indicating a need for a higher dosage (26).
In patients taking deferoxamine, a fall in serum
ferritin was noted in 23/40 patients (57.5%) after 6
months, and in 25/40 (62.5%) after 24 months of
starting the trial. The mean drop was significant at
those follow-up periods.
At the beginning of the trial, the two groups had
comparable mean serum ferritin levels (p=0.637).
In the L1 group, the mean drop in serum ferritin
was higher after 6 months and after 12 months than
with deferoxamine, although this difference was not
statistically significant (1063t440 mg/l compared to
337t189 mg/l (p=0.270) at 6 months; and
684t449 mg/l versus 389t284 mg/l at 12 months
(p=0.578) in L1 and deferoxamine groups, respec-
tively). Later on, the drop in ferritin was almost a
similar in the two groups. Our results are similar to
previous studies that showed similar effect of the
two drugs on serum ferritin concentration in doses
similar to those used in the present study (27–29),
although in one study there was an increase in liver
iron with L1 (27).
L1 was well tolerated, neither the reduction nor
the cessation of L1 was required because of adverse
effects. Only one patient was lost to follow up. The
arthropathy observed in six patients was transient
and mild to moderate in severity. Pain was relieved
by a short course of NSAIDs. There was no relation
between the presence of these symptoms and the
presence of the different autoantibodies tested
before or after the therapy. The changes in the
liver enzyme ALT in patients who were HCV
negative were also transient and settled without
discontinuation of L1 therapy.
In our trial, adverse effects associated with
Desferal use can be grouped into two main
categories, namely local skin reactions and more
serious toxic effects including visual and auditory
abnormalities or growth retardation. It has been
recognized that most toxic effects of deferoxamine
have been observed in patients during administra-
tion of doses exceeding 50 mg/kg/d, or smaller doses
in the presence of very modestly elevated body iron
burdens (1). These toxic complications can be
minimized by proper dose adjustments. One such
method is limiting the daily dose/kg body weight to
a deferoxamine to ferritin ratio of 0.025 (3).
In conclusion, L1 appears to be a relatively safe
chelator at a dose of 75 mg/kg/d. However, at this
dose urinary iron excretion was not enough to
induce a negative iron balance in our patients. On
the other hand, based on ferritin level, it was found
that L1 is as effective as deferoxamine, which may
be related to a better compliance. All patients stated
a clear preference for using L1 compared with
subcutaneous deferoxamine, and the patients
apparent compliance with the drug throughout
the trial was excellent. Increasing the dose of
L1 or combining subcutaneous deferoxamine with
L1 therapy are two methods by which efficacy
of iron chelation with L1 can be improved in
patients inadequately chelated by a daily dose of
75 mg/kg/d.
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